Olivier Charmeil

Sanofi’s Acquisition of Provention Bio Expands Immune-Mediated Disease Portfolio

(IN BRIEF) Sanofi has agreed to acquire Provention Bio, a U.S.-based biopharmaceutical company focused on preventing and intercepting immune-mediated diseases,…

1 year ago

Sanofi to add Rezurock™ to its transplant portfolio with the acquisition of Kadmon Holdings, Inc.

Adds Rezurock™ (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease…

3 years ago

Sanofi Pasteur starts phase III clinical trial in India for its investigational rotavirus vaccine manufactured by its affiliate Shantha Biotechnics in Hyderabad, India

The live, oral, ready-to-use tetravalent rotavirus vaccine candidate is designed to protect young children from severe diarrhea Lyon, France, 15-10-2014 —…

10 years ago

Sanofi Pasteur announced its pediatric pentavalent vaccine Shan5™ received prequalification status from the World Health Organization

Shan5™ is the first vaccine jointly developed by the Indian company and its parent company Sanofi Pasteur  WHO’s decision allows for…

10 years ago